Main Article Content

Ali Farhan Hashoosh ali_fr@uomisan.edu.iq
Hmood Madhi Hasan Hmood.mcm@uomisan.edu.iq


Abstract

Abstract:


This research deals with the three types of COVID-19 vaccines (AstraZeneca vaccine, Sinopharma, and Pfizer-Biontech) in terms of manufacturing, producing companies, and the countries in which the tests were conducted, in addition to the teams that provided the researchers with these vaccines. In this research, a statistical study about the effectiveness of these vaccines is presented and the extent of their impact on the vaccinator if he was healthy or carrying some other diseases. After that, a statistical study is presented, comparing it between the types of vaccines and which one is the most used, by taking a sample from the State of Iraq, Maysan Governorate, consisting of 60 individuals who took the vaccine. a special questionnaire was used for this purpose and the results were, another questionnaire about the acceptance of the local community results were analyzed using an SPSS program. Another questionnaire about the acceptance of the local community representing Maysan Governorate to obtain the vaccine for the emerging coronavirus, COVID-19. The questionnaire was also delivered to statistical specialists before submitting the questionnaire. Important results were obtained, including the most received vaccine Pfizer-BioNTech and Sinopharm, by 40% and all those who received the vaccine were not infected after taking the vaccine.

Downloads

Download data is not yet available.

Article Details

How to Cite
Hashoosh, A. F., & Hasan, H. M. (2024). Investigation Of The Effects Of Three COVID-19 Vaccines. Al-Kitab Journal for Pure Sciences, 9(01), 34–50. https://doi.org/10.32441/kjps.09.01.p3
Section
Articles

References

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.

Ndwandwe D. COVID-19 vaccines Duduzile Ndwandwe and Charles S Wiysonge. Curr Opin Immunol. 2021;71:111-116.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.

Ndwandwe D. COVID-19 vaccines Duduzile Ndwandwe and Charles S Wiysonge. Curr Opin Immunol. 2021;71:111-116.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.

Yang L, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128.

Hashoosh AF, Basirzadeh H. Stability on optimal control problems and multi-population mathematical models. Util Math. 2023;120:500-505.

Farhan Hashosh A, Basirzadeh H. Routh stability criterion and Lyapunov-Routh method in control theory. Int J Nonlinear Anal Appl. 2024;15(5):111-120.

Hashoosh AF. Special methods controllability and observability in optimal control systems. Al-Kitab J Pure Sci. 2024;8(2):78-93.

Daniel SJ. Education and the COVID-19 pandemic. Prospects. 2020;49(1):91-96.

Malik AA, et al. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495.

Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946.

UNICEF. Number of vaccine approvals. 2021 May 21.

Zahraei SM, et al. Immunization coverage of children aged 24–35 months in the Islamic Republic of Iran: a national cluster coverage survey. East Mediterr Health J. 2022;28(2):121-129.

Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm, and AstraZeneca vaccines to stop COVID-19: a review and discussion. 2021.

AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization [Internet]. 2021. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization.html

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [Internet]. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1

World Health Organization. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know. World Health Organization. 2021.

Zee Business. Coronavirus Vaccine Covishield: Side effects, benefits of Serum Institute-AstraZeneca vaccination. Zee Business. 2021.

AstraZeneca COVID-19 Vaccine (AZD1222) [Internet]. Available from: https://www.precisionvaccinations.com/vaccines/astrazeneca-covid-19-vaccine-azd1222

Logunov DY, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.

Formeister EJ, et al. Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System data. JAMA Otolaryngol Head Neck Surg. 2021;147(7):674-676.

Wang H, Zhang Y, Huang B. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713-721. doi: 10.1016/j.cell.2020.06.008.

Faso B, Equatorial Guinea. Sinopharm/BIBP COVID-19 vaccine.

Xia S, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951-960.